Lupin Limited has received tentative approval for its Empagliflozin & Metformin Hydrochloride extended-release (ER) tablets, 5 mg/1,000 mg, 10 mg/1,000 mg, 12.5 mg/1,000 mg, and 25 mg/1,000 mg, from United States Food & Drug Administration (USFDA). The product will be manufactured at Lupin's Nagpur facility in India.